Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Elliott L. Fineman | M | - |
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 20 years |
| Christopher Viehbacher | M | 64 |
Glaxo Wellcome Plc
| 13 years |
| Ngai Man Ng | M | 62 |
University of London
| 4 years |
| Chi Keung Wong | M | 65 |
University of London
| 7 years |
| Stewart James Jackson | M | 59 |
University of London
| 5 years |
| Christopher Martin Nutting | M | - |
University of London
| 7 years |
| Clive R. Wood | M | 63 |
University of London
| 8 years |
| Susanna Chau | F | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| Gordon Ng | M | 59 |
University of London
| 5 years |
| Hussam bin Saud Al-Saud | M | 64 |
University of London
| 4 years |
| Adam David Lindemann | M | 51 |
University of London
| 7 years |
| Gavin Choy | M | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| Hiu Tung Tse | M | 59 |
University of London
| 7 years |
| Penny Dash | M | - |
University of London
| 6 years |
| Robert Alexander Ingram | M | 81 |
Glaxo Wellcome Plc
| 14 years |
| Kang Bor Lee | M | 70 |
University of London
| 6 years |
| Richard Sykes | M | 79 |
Glaxo Wellcome Plc
| 5 years |
| Michael Molkentin | M | 69 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | 8 years |
| Stephen Dilly | M | 64 |
University of London
| 7 years |
| Jonathan Fowler | M | - |
University of London
| 3 years |
| Saleh bin Shahid | M | 64 |
University of London
| 4 years |
| Wing Hong Ng | M | 70 |
University of London
| 3 years |
| Jayne O’Brien | F | - |
University of London
| 4 years |
| Man Shing Chi | M | 60 |
University of London
| 4 years |
| W. M. H. Jaim | M | - |
University of London
| 3 years |
| Chong Choon Chan | M | 68 |
University of London
| 3 years |
| Caroline Harris | M | - |
University of London
| 1 years |
| Paramalingam | M | - |
University of London
| 3 years |
| Richard Chilcott | M | - |
University of London
| 4 years |
| Ashley Alder | M | 65 |
University of London
| 3 years |
| Rajesh Kumar | M | 57 |
University of London
| 3 years |
| Mark J. Golding | M | - |
University of London
| 3 years |
| Nick Flinn | M | - |
University of London
| 4 years |
| Boon Siew Wong | F | 56 |
University of London
| 4 years |
| Mei Tjuen Tjioe | F | 66 |
University of London
| 4 years |
| Wai Yip Tang | M | 66 |
University of London
| 4 years |
| Boon Thye Koh | M | 66 |
University of London
| 3 years |
| James Alistair Preston | M | - |
University of London
| 4 years |
| Chi Kwong Wong | M | 62 |
University of London
| 4 years |
| Nicholas Bryan-Brown | M | 64 |
University of London
| 3 years |
| Swee Long Liu | M | 63 |
University of London
| 3 years |
| Kok Cheng Su | M | 56 |
University of London
| 4 years |
| Ishak bin Abdul Razak | M | 70 |
University of London
| 1 years |
| Kwok Wing Chan | M | 70 |
University of London
| 1 years |
| Kim Hung Lee | M | 54 |
University of London
| 4 years |
| David Packham | M | - |
University of London
| 3 years |
| Melanie Braunold | F | - |
University of London
| 3 years |
| Wing Lun Leung | M | - |
University of London
| 4 years |
| Il-Yung Kim | M | 67 |
University of London
| 1 years |
| Uzir bin Abdul Malik | M | 79 |
University of London
| 3 years |
| Koon Man Chung | M | 65 |
University of London
| 4 years |
| Kin Ping Yim | M | 69 |
University of London
| 1 years |
| Wan Chee Chun | F | - |
University of London
| 4 years |
| Rateb Ahmed Ibrahim Al-Wazani | M | 92 |
University of London
| 3 years |
| Jaikrishna Patel | M | - |
University of London
| 4 years |
| Yui Keung Wong | M | 70 |
University of London
| 3 years |
| Rana Partap Chauhan | M | - |
University of London
| 7 years |
| Xin Zhong Li | M | 66 |
University of London
| 3 years |
| Andrew F. Moulder | M | - |
University of London
| 4 years |
| Rexford A. Darko | M | - |
University of London
| 3 years |
| Boon Hoe Ooi | M | 58 |
University of London
| 4 years |
| Mazen Mohammad Abdulrahman Al-Bashir | M | 68 |
University of London
| 1 years |
| Jonathan S. Tudor | M | - |
University of London
| 3 years |
| Anand Gautam | M | - |
University of London
| 3 years |
| Andy Reed | M | - |
University of London
| 4 years |
| Timothy David Voake | M | - |
University of London
| 4 years |
| Yee Seng Cheng | M | 76 |
University of London
| 3 years |
| Kai Nang Chan | M | 79 |
University of London
| 3 years |
| Paul Gazzard | M | 52 |
University of London
| 4 years |
| Faridah binti Mohammad | F | 63 |
University of London
| 3 years |
| Jivraj Kabir | M | - |
University of London
| 5 years |
| Martin Buckland | M | 69 |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | - |
| Bolaji Odunsi | M | 62 |
University of London
| 4 years |
| Ignacio Sanín Bernal | M | 76 |
University of London
| 3 years |
| Kevin George Bilyard | M | - |
University of London
| 3 years |
| Christian William Thwaites | M | - |
University of London
| 4 years |
| Christopher Charles Warkup | M | - |
University of London
| 4 years |
| Siak Hee Tan | M | 69 |
University of London
| 4 years |
| Kim Meow Lee | M | 65 |
University of London
| 3 years |
| Chee Leong Wai | M | 66 |
University of London
| 3 years |
| Kwok Man Chu | M | 67 |
University of London
| 3 years |
| Lin Chung Tse | M | 63 |
University of London
| 17 years |
| Ki Chi Yip | M | 58 |
University of London
| 3 years |
| Kay Joo Chia | M | 77 |
University of London
| 3 years |
| Say Teik Ooi | M | 64 |
University of London
| 3 years |
| Pahamin Abdul Rajab | M | 78 |
University of London
| 3 years |
| Pakhruddin bin Sulaiman | M | 67 |
University of London
| 3 years |
| Sheila A. Lines | F | - |
University of London
| 3 years |
| Ting Mei Fu | M | 57 |
University of London
| 1 years |
| King Yan To | M | 65 |
University of London
| 3 years |
| Chung Yu Tsang | M | - |
University of London
| 4 years |
| Sam Rahman | M | - |
University of London
| 3 years |
| Chung Wing Lai | M | 77 |
University of London
| 3 years |
| Wai Tak Sung | M | 66 |
University of London
| 3 years |
| Ron Olivier | M | - |
University of London
| 4 years |
| Tan Chee Keong | M | - |
University of London
| 4 years |
| Andrew Maxwell | M | - |
University of London
| 2 years |
| Antonio Luis P. de Castro | M | - |
University of London
| 1 years |
| Hon Tak Ng | M | 64 |
University of London
| 4 years |
| Ka Keung Chan | M | - |
University of London
| 14 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 95 | 95.00% |
| United States | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Harren Jhoti
- Personal Network
